Siratro Extract BG - Cosmesi.it
Siratro Extract BG - Cosmesi.it
Siratro Extract BG - Cosmesi.it
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
NIKKO CHEMICALS CO., LTD.<br />
1-4-8 NIHONBASHI-BAKUROCHO, CHUOKU, TOKYO, 103-0002, JAPAN Email: inter@nikkol.co.jp www.nikkol.co.jp<br />
Natural Emulsifier for Sens<strong>it</strong>ive Skin Care<br />
Lecinol S-10<br />
Anti-inflammatory<br />
inflammatory<br />
Hydrogenated lec<strong>it</strong>hin derived from soy bean. Contains 25-30% of Phosphatidyl Choline. Natural<br />
emulsifier w<strong>it</strong>h anti-inflammatory properties. Effectively reduces irr<strong>it</strong>ation. Decreases irr<strong>it</strong>ation potential<br />
of other surfactants. Enhances anti-inflammatory properties of oil-soluble actives (e.g. Stearyl<br />
Glycyrrhetinate). Emulsions made w<strong>it</strong>h Lecinol S-10 enhance percutaneous of active ingredients.<br />
Prevention of corneocytes’ damage<br />
caused by Sodium Lauryl Sulfate (SLS).<br />
Closed patch (SLS: 5%); after 72 hours.<br />
Microscope photograph of<br />
corneocytes.<br />
Lecinol S-10 protects stratum corneum<br />
from damage by strong detergents.<br />
Non-treated cells<br />
Cells treated w<strong>it</strong>h<br />
1% Lecinol S-10<br />
Anti-stinging effect (in vivo)<br />
Weak Strong<br />
Average stinging score<br />
3<br />
2<br />
1<br />
Before<br />
After 1 week<br />
application of<br />
Lecinol S-10<br />
(1.0%)<br />
Water<br />
NEW<br />
DATA<br />
0.1%<br />
methylparaben<br />
solution<br />
Anti-inflammatory effect: inhib<strong>it</strong>ion of<br />
Prostaglandin E2 (in v<strong>it</strong>ro)<br />
Application of Lecinol S-10 at 1.0% significantly<br />
reduced average stinging score against<br />
methylparaben solution (after 1 week; n=13).<br />
Control: Water 0.1% MP sol.<br />
Number of subjects who showed<br />
reduction of stinging score after 1 week<br />
application of Lecinol S-10 (1.0%)<br />
1 (8%) 7 (54%)<br />
2009-12